Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation

Publisher： John Wiley & Sons Inc

E-ISSN： 1537-2995|55|11|2709-2713

ISSN： 0041-1132

Source： TRANSFUSION, Vol.55, Iss.11, 2015-11, pp. : 2709-2713

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison between biosimilar filgrastim vs other granulocyte‐colony stimulating factor formulations (originator filgrastim, peg‐filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 2, 2015-04 ,pp. : 293-296

John Wiley & Sons Inc

Access to resources Recommend Favorite

Poor peripheral blood stem cell mobilization affects long‐term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation

By  

JOURNAL OF CLINICAL APHERESIS, Vol. 33, Iss. 1, 2018-02 ,pp. : 29-37

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rhabdomyolysis in a Healthy Peripheral Blood Stem Cell Donor following Mobilization with Filgrastim

By  

Transfusion Medicine and Hemotherapy, Vol. 36, Iss. 2, 2009-03 ,pp. : 135-137

Karger

Access to resources Recommend Favorite

Filgrastim versus TBO‐filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 12, 2015-12 ,pp. : 1128-1132

John Wiley & Sons Inc

Access to resources Recommend Favorite

Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 93-97

Karger

Access to resources Recommend Favorite